Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + pertuzumab + octreotide
- Development stage
- Unknown
- Lead developer
- Sarah Cannon Research Institute
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous, Intramuscular
01
Overview
bevacizumab + pertuzumab + octreotide is a combination therapy investigated by SCRI Development Innovations, LLC for the treatment of advanced neuroendocrine carcinoma. The regimen consists of bevacizumab, a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis; pertuzumab, a humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 (HER2), preventing it from pairing with other HER family members; and octreotide (Sandostatin LAR), a long-acting somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and exert anti-proliferative effects on tumor cells.
- Other names
- Bevacizumab, Pertuzumab, and Sandostatin combination
02
Targets
SSTR2 (Somatostatin receptor type 2)VEGFA (Vascular endothelial growth factor A)SSTR5 (Somatostatin receptor 5)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on bevacizumab + pertuzumab + octreotide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + pertuzumab + octreotide.